Keeping Track: Approvals For Pfizer's Eucrisa, Vericel's Maci; Submissions From Flexion, AcelRx, Ironshore

The latest drug development news and highlights from our FDA Performance Tracker.

FDA's drug and biologic centers each produced a novel approval last week, with Pfizer Inc.'s Eucrisa and Vericel Corp.'s Maci.

Eucrisa (crisaborole), an atopic dermatitis treatment that came from Pfizer's acquisition of Anacor Pharmaceuticals Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approvals

More from Product Reviews